Hypophosphatasia: 2026 so far

Evidence broadened from claims data to adult and pediatric cases.

In the months covered, routine-care insurance claims data and several real-world reports linked asfotase alfa with outcomes people can feel, including fewer billed fractures and better mobility/function after starting treatment. The January claims analysis reported fewer billed fractures after initiation and changes in billed follow-up services. A small adult case series described improved walking/independence and less pain when treatment began in adulthood for childhood-onset disease. One case report provided an imaging example of a previously slow-healing foot fracture that fully consolidated by 13 weeks after starting asfotase alfa. At the same time, these reports emphasized that responses differed from person to person, and that severe early-onset disease could still have serious outcomes. This means the published evidence so far in 2026 has increasingly tracked fractures, pain, and function alongside labs and imaging, but it has mostly come from observational datasets and small series rather than controlled trials.

Research covered in: January 2026, April 2026, June 2026

Reports highlighted fluctuating response and potential contributors over time.

Later reports added detail that improvement on asfotase alfa was not always steady in real life. Worsening was described during a treatment interruption and during a period when neutralizing antibodies (antibodies that can block a medicine's effect) were detected in one child. A long follow-up in siblings described deterioration after an unplanned stop and recovery after restarting. Another single-patient report described rickets (soft, weak bones from poor mineralization) returning when neutralizing antibodies were present and improving again after a dose increase and continued therapy, without proving cause-and-effect. Single-patient safety/complication details were also reported, including injection-site lipodystrophy (loss or change of fat under the skin) and nephrocalcinosis (calcium deposits in the kidneys) with normal kidney function in one child, and a report where a pseudofracture (a stress-related bone crack) healed while CPPD (calcium pyrophosphate crystal disease, a crystal-related joint problem) persisted. In the months covered, these experiences documented that symptoms can move in different directions during therapy, and that different HPP-related problems may not improve at the same pace.

Research covered in: July 2026

Registry studies clarified symptom burden beyond bone density labels.

Registry analyses in the months covered highlighted that adult HPP often involves chronic musculoskeletal pain (long-lasting pain in muscles, bones, or joints) and limits on daily function. This was also described in people categorized as "non-skeletal." Fractures were frequent in adult cohorts. Across registries, broad quality-of-life and function scores could look similar between skeletal and non-skeletal groups. At the same time, skeletal HPP showed more dental issues and mobility-related features, such as abnormal gait and use of mobility aids. A separate registry report noted that classic osteoporosis on bone density scans appeared uncommon in the subset with scans, reinforcing that bone density alone may not capture HPP-related fragility in these datasets. In the months covered, this research repeatedly treated pain, function, and fracture history as central outcomes, not just bone density results.

Research covered in: June 2026, August 2026

Multiple studies converged on combining low ALP with add-on tests.

Across several adult studies, persistently low alkaline phosphatase (ALP) was treated as an important clue, but not a stand-alone answer. Studies reported clearer separation when low ALP was paired with PLP (a vitamin B6-related blood marker) and/or other substrate markers, plus ALPL genetic testing (a DNA test for the ALPL gene). Proposed adult criteria performed best when genetic and biochemical substrate information was included. In contrast, symptom-only approaches separated genetically positive and negative adults poorly. Other work proposed practical scoring approaches using very low ALP plus a small set of clinical features. Additional cohorts reinforced that low ALP can be rare in routine testing yet associated with fractures, pain/fatigue, and dental issues. They also suggested that adding markers, such as PPi and urine PEA (additional lab measures of HPP-related substrates) in one clinic sample, could help distinguish genetic HPP from other causes of low ALP. Overall, the reports available so far in 2026 repeatedly showed that diagnostic certainty depends heavily on which confirmatory tests are obtained, not on ALP alone.

Research covered in: February 2026, May 2026, July 2026, August 2026

A structured pathway identified confirmed cases, carriers, and gray-zone suspects.

In September, a hospital screening pathway that started from persistently low ALP used follow-up testing, including genetics and a vitamin B6-related marker, to sort children into confirmed HPP, asymptomatic carriers, and a "suspected" group. The report described dental differences and slowed growth as common in milder pediatric cases found through this approach. It also used functional testing (lab work to see how a gene change behaves) to help reclassify a small number of previously uncertain variants. The study also noted neurobehavioral concerns (behavior and development concerns) observed in the screened population without establishing causality. In the months covered, this screening approach was presented as a practical way to reduce missed recognition in children, while still leaving a meaningful subset in an unresolved diagnostic category.

Research covered in: September 2026